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Lenalidomide mechanism of action has been shown to modulate the different components of the immune system.
A 68-year-old lady presented to us with severe backache and was then diagnosed with MM. Lenalidomide started
as per protocol along with dexamethasone. Later, she presented with complaints of generalized weakness and her
workup showed significant blast cells with Pan-B-cell markers consistent with secondary B-ALL. The reported
incidence of secondary Acute Lymphocytic Leukemia is 2.3%. The development of more aggressive neoplasm in a
patient with prior malignancy dictates a poor outcome and hence such patients should be enrolled in a clinical
trial whenever available.

Abbreviations
ALL:
Acute Lymphoblastic Leukemia
BMB:
Bone Marrow Biopsy
CR:
Complete Remission
MM:
Multiple Myeloma
OS:
Overall Survival
PFS:
Progression Free Survival
s-ALL:
Secondary Acute Lymphoblastic Leukemia
SPM:
Second Primary Malignancies
vGPR:
Very Good Partial Response
1. Introduction
Lenalidomide is a very active agent in hematologic malignancies. Its’
mechanism of action has been shown to modulate different components
of the immune system by altering cytokine production, regulating T cell
co-stimulation, and augmenting the Natural Killer (NK) cell cytotoxicity
[1]. Lenalidomide binds cereblon to form a complex that then targets
B-cell transcription factors, Ikaros family zinc finger proteins (IKZF) 1
and 3, for proteasome degradation and loss of which is thought to play
an important role in lenalidomide’s therapeutic effect [2]. It was first
approved for the treatment of MM and now is the standard of care in the

first line in combination with proteasome inhibitors and steroids.
Lenalidomide is also the preferred agent for maintenance therapy in
standard-risk MM. In a randomized trial, lenalidomide maintenance
until progression was associated with better progression-free survival
compared to no maintenance in patients with MM [3]. Therapy-related
malignancies are a sub-group of secondary malignancies during which
exposure to prior chemotherapy or radiotherapy is a key factor in the
pathogenesis of secondary cancer. The reported incidence of secondary
Acute Lymphocytic Leukemia (s-ALL) who previously had primary ma
lignancy is 2.3% with a high prevalence of pre-B-cell immunopheno
type, however, a study on s-ALL, multiple myeloma was not observed to
be primary malignancy [4]. Secondary malignancies are a known albeit
rare complication of long-term lenalidomide therapy. However, the
incidence of s-ALL because of lenalidomide is very low. We report a case
of a patient with IgG Kappa multiple myeloma who developed pre-B cell
ALL during maintenance therapy with lenalidomide.
2. Case presentaion
A 68-Year-old woman, known case of hypertension, chemistry pro
fessor by profession, widowed, mother of three children, resident of
Karachi, Pakistan, presented to our institution in the fall of 2009 with a
one-month history of generalized weakness and severe backache. She
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had no other symptoms. Complementary examinations and laboratory
investigations were performed. Her physical examination was
completely normal. An x-ray lumbosacral spine showed compression
collapse of the L2 vertebral body. A routine complete blood count at the
time of presentation showed hemoglobin of 10.4 g/dL, normal white
blood cell count, and platelets of 159,000/μL. The erythrocyte sedi
mentation rate (ESR) was elevated to 62 mm/h (normal <20 mm/h).
The blood urea increased to 8.1 mmol/L (normal <7.1 mmol/L) and
creatinine increased to 140 μmol/L (normal <133 μmol/L). The results
of a random blood glucose test, liver function, electrolytes, and lipid
profile were all normal. Serum protein electrophoresis revealed a raised
serum kappa paraprotein band with IgG levels of 36.3 g/l (Normal 6.2913.5 g/l). Bence-Jones proteins in the urine were negative. Her beta 2
microglobulin was raised (2516.00 ng/ml). A bone marrow biopsy
(BMB) was performed which showed 41% pleomorphic plasma cells.
These findings were consistent with the diagnosis of MM; ISS-III as per
International staging system (ISS) of multiple myeloma. Her bone
marrow cytogenetics was normal (46XX). Fish analysis for high-risk
features was not sent. Her skeletal survey showed innumerable small
punched-out lytic lesions with diffuse involvement of the skeleton.
(Fig. 1)
She was started on lenalidomide at a dose of 25 mg daily for 21 days,
followed by 7 days off, for a 28-day cycle with dexamethasone was given
at a dose of 40 mg weekly and pamidronate 90 mg IV monthly. She also
received aspirin for thromboembolic prophylaxis. The patient achieved
a very good partial response (VGPR). She was then switched to main
tenance lenalidomide 10 mg/day. She then achieved a complete he
matologic response (CR) with complete disappearance of the
monoclonal protein in the serum with 4% plasma cells in bone marrow
aspirates in 17 months from diagnosis. Autologous stem cell transplant
(ASCT) was offered but refused by the patient. She was kept on sur
veillance for 22 months and followed from time to time in the clinics via
clinical examination and lab investigating with SPEP and IgG levels. She
developed disease progression, evident when she presented with
increased lethargy and fatigue. Furthermore, investigations revealed
raised kappa protein band with an increased appearance of IgG levels
and BMB confirmed the reappearance of a significant no of plasma cells.
She was then re-started on lenalidomide with a dose of 10 mg daily for
21 days followed by 7 days off, for a 28-day total cycle along with
dexamethasone 40 mg weekly. She again achieved a CR with less than
4% plasma cells in bone marrow aspirate in 12 months. She continued
taking lenalidomide from 2014 till 2020.
She then presented in June 2020 with complaints of generalized
weakness and loss of appetite for two months. General physical exami
nation showed pallor skin and bilateral pedal edema. Her systemic ex
amination was unremarkable. Her complete blood count showed

hemoglobin of 7.8 g/dl, white blood cell counts 34.5 × 10E9/L, platelets
30 × 10E9/L, and 79% blast cells (Fig. 2). Bone marrow biopsy was
performed which showed hyper-cellular specimens exhibiting diffuse
infiltration with blast cells that constitute around 85% of the total
nucleated non-erythroid cell population (Fig. 3a,b). Immunophenotyp
ing by flow cytometry showed blast cells reactivity with Pan-B-cell
markers i.e., CD19 and cCD79a along with HLA-DR, CD45, CD34, and
Tdt. (Fig. 4). Overall findings were consistent with secondary B-cell
acute lymphoblastic leukemia (B-ALL). Limited cytogenetic panel was
performed. Translocation of (8;14) (q24; q32), T-P53 as well as deletion
of 11q23 was not detected. Philadelphia chromosome (Ph.) was checked
which was also negative. Her serum protein electrophoresis and
immunofixation showed no evidence of monoclonal gammopathy.
After negative COVID testing, she was admitted and commenced on
modified Hyper-CVAD protocol with, Dexamethasone 40 mg per oral
daily on days 1 through 4 and 11 through 14, Vincristine 1mg/m2-on
day 4 and 11, Doxorubicin 25mg/m2-on day 4. On day 8 of chemo
therapy, she developed worsening shortness of breath and fever. Chest
X-Ray showed bilateral infiltrates. Extensive workup including all the
viral markers, pan-cultures, fungal markers including BDG and Gal
actomannan were performed and they came out to be negative. COVID
PCR was repeated, and which was driven out to be positive. The patient
rapidly developed respiratory failure and eventually succumbed to the
complications of coronavirus disease 5 days from diagnosis.

Fig. 2. Peripheral blood film showing presence of significant number of atyp
ical lymphoid/blast cells.

Fig. 1. a,b: Skeletal survey shows innumerable small punched out lytic lesions involving skull pelvic bones diffusely, lumbosacral spine, mandible, distal left femur.
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Fig. 3. a,b: Hyper-cellular specimen exhibiting diffuse infiltration with blast cells that constitute around 85% of the total nucleated non-erythroid cell population.
These blast cells are small to medium in size having high nuclear to cytoplasmic ratio, scanty agranular cytoplasm with vacuolations, open chromatin and prominent
nucleoli. Normal hematopoiesis is suppressed.

cumulative incidence of all second primary malignancies (SPM) at 5
years in patients treated with lenalidomide containing regimen was
6.9% compared with 3.8% in patients who were treated without lena
lidomide [12]. Analysis of the Myeloma XI trial revealed that solid
malignancies are the most common SPM diagnosed. Secondary hema
tological malignancies are rare with acute myeloid leukemia (AML) and
myelodysplastic syndrome being the most common reported [13].
Therefore, it can be concluded the risk of SPM is a very small, albeit a
well-described complication of long-term lenalidomide therapy. Litera
ture does report this unique feature of lenalidomide associated with the
development of s-ALL [14–16]. Germans Sharon Koorse et al., reported
two cases of lenalidomide associated with s-ALL in patients who previ
ously had multiple myeloma and underwent ASCT and later on devel
oped s-ALL while on maintenance lenalidomide, however because of the
rarity and unique features of lenalidomide induced s-ALL in MM pa
tients, the clinicopathological features of this disease remains poorly
understood [17].
The incidence of therapy-related to secondary acute lymphocytic
leukemia (s-ALL) is very low. Studies have reported the incidence be
tween 1.9%-9% of all patients with hematological SPM [18]. Clinically
t-ALL appears to be more common in the older age group with a median
latency to the diagnosis of approximately 6.8 years. When compared to
de novo ALL, t-ALL is found to have a higher incidence of complex
karyotype, MLL gene rearrangement, and monosomy of 5 and 7.
Studies have shown frequent detection of chromosome 11q23 ab
normalities in therapy related-secondary ALL, which is the most com
mon cytogenetic alteration found in s-ALL. Cases of s-ALL without
chromosome 11q23 have rarely been described. Our patient developed
s-ALL with no detection of chromosome 11q23 abnormality which is
also unique to this case. A study on s-ALL showed that the median time
from primary malignancy to the development of s-ALL was 67 months,
however, our patient developed s-ALL approximately 11 years later after
her primary malignancy hence, we still have limited data available to
define the optimal duration for the development of s-ALL after primary
malignancy [19]. Antecedent diagnosis of a hematological malignancy
is seen in 1/3rd of the patients with myeloma present in 12% of these
cases. Interestingly, there does not appear to be any difference in the
frequency of B or T cell phenotype [20].
Several trials have evaluated different treatment protocols for ALL.
Combination chemotherapy is the primary treatment modality for pa
tients with ALL, to rapidly restore bone marrow function and attain a
complete remission (CR). More than 80 % of newly diagnosed adults
with ALL enter CR with such intensive chemotherapy regimens. In a
retrospective analysis of over 1000 ALL, the CR rates of s -ALL were
comparable to de novo ALL. In addition, patients who went on to receive

3. Discussion
There is a remarkable advancement in the development of treatment
modalities and surveillance techniques of cancer which has resulted in
marked improvement in cancer survival. Hence second primary malig
nancies are becoming an increasingly common problem for both clini
cians and survivors. Multiple myeloma is a classic example. MM was
thought to be a fatal disease with a short life expectancy. However,
introduction to the various novel agents such as primary immunomod
ulatory agents as well as the proteasomal inhibitors and more recently
monoclonal antibodies, the clinical course of MM can be altered to
behave as a chronic disease with eventual remissions and relapses
requiring multiple lines of treatment, therefore, increasing the risk for
the development of secondary malignancies in MM survivors [5]. Triplet
combinations with proteasome inhibitors, immunomodulators, and
dexamethasone are currently the standard of care in MM. Long-term
follow-up of len-Dex combination treatment with Bortezomib showed
sustained survival benefits [6]. Maintenance therapy in MM has been
considered to be a key component for at least a decade. Updated results
of the Myeloma XI trial continued to show a highly statistically signifi
cant improvement in PFS with lenalidomide maintenance with a hazard
ratio of 0.45 [7]. There are very rare documented cases of s-ALL after
lenalidomide maintenance in MM. The impact of the long-term use of
lenalidomide on the kinetics of minimal residual disease (MRD) has also
been evaluated.. A retrospective analysis of 139 patients who received
lenalidomide maintenance and whose levels of MRD were measured
during the treatment period by next-generation-sequencing (NGS) or
flow cytometry maintenance lenalidomide correlated with an increased
depth of the disease response. Maximum response was achieved in
38.1% of the patients during maintenance. In addition, 34% of patients
who were MRD positive after induction therapy became MRD negative
with lenalidomide maintenance therapy leading to their improvement in
PFS [8]. The use of NGS in patients with secondary malignancies may
highlight crucial steps in their management. We have not performed
NGS study for our patient because of its unavailability in our institute.
NGS study that can identify genomic markers such as IKZF1, TP53,
CDKN2A, RB1, PAX5, DNMT3A, RUNX1, AXL1 may help to elaborate
personalized therapy in certain patients with aggressive neoplasms [9].
The landmark trial of long-term maintenance lenalidomide after
stem cell transplantation reported a statistically significant increase in
the incidence of second primary malignancies (SPM) of 3.1 vs 1.2 per
100 patient-years [10]. In transplant-ineligible patients, the addition of
lenalidomide to melphalan and prednisone (MP-R) demonstrated the
incidence of SPM of 7% vs. 3% in the MP alone [11]. Palumbo et al
reported in a meta-analysis of newly diagnosed MM patients that the
3
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Fig. 4. Flow Cytometer, CD45 staining was performed and gating was done on dim CD45 positive blast (85%)cells population. This population shows reactivity with
Pan-B-cell markers i.e. CD19 and cCD79a along with HLA-DR and CD45. This population also shows positivity to CD34 and Tdt

an allogeneic stem cell transplant in CR1 were found to have similar PFS
and OS when compared to de novo ALL patients [21]. These results are
in contrast to another retrospective analysis of 92 patients reporting a
dismal outcome regardless of treatment modality especially in patients
> 60 years [22]. Nonetheless, allogeneic stem cell transplantation ap
pears to be the only curative option with a leukemia-free survival and
overall survival of 47% and 51% [23].
Here we report a patient, who was on maintenance lenalidomide for
a very long period for MM and then developed s-ALL 11 years after her
diagnosis.

4. Conclusion
MM patients who are on maintenance treatment should be carefully
followed with bone marrow examination, peripheral blood film review,
flow cytology, and gene tests. The development of more aggressive
neoplasm in a patient with prior malignancy dictates a poor outcome
and required further assessment; hence such patients should be enrolled
in clinical trials whenever available in order to understand them
profoundly.
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